Literature DB >> 30325767

Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.

Daniela K van Santen1, Jannie J van der Helm1,2, Giota Touloumi3, Nikos Pantazis3, Roberto Muga4, Barbara Gunsenheimer-Bartmeyer5, M John Gill6, Eduard Sanders7,8, Anthony Kelleher9, Robert Zangerle10, Kholoud Porter11, Maria Prins1,12, Ronald B Geskus1,8,13,14.   

Abstract

BACKGROUND: Most studies on hepatitis C virus (HCV)/HIV-coinfection do not account for the order and duration of these two infections. We aimed to assess the effect of incident HCV infection, and its timing relative to HIV seroconversion (HIVsc) in HIV-positive MSM on their subsequent CD4+ T-cell count and HIV RNA viral load trajectories.
METHODS: We included MSM with well estimated dates of HIVsc from 17 cohorts within the CASCADE Collaboration. HCV-coinfected MSM were matched to as many HIV monoinfected MSM as possible by HIV-infection duration and combination antiretroviral therapy (cART) use. We used multilevel random-effects models stratified by cART use to assess differences in CD4+ cell count and HIV RNA viral load trajectories by HCV-coinfection status.
FINDINGS: We matched 214 (ART-naive) and 147 (on cART) HCV-coinfected MSM to 5384 and 3954, respectively, matched controls. The timing of HCV seroconversion (HCVsc) relative to HIVsc had no demonstrable effect on HIV RNA viral load or CD4+ cell count trajectories. In the first 2-3 years following HCVsc CD4 cell counts were lower among HCV-coinfected MSM, but became comparable with HIV monoinfected MSM thereafter. In ART-naive MSM, during the first 2 years after HCVsc, HIV RNA viral load levels were lower or comparable with HIV monoinfected, tending to be higher thereafter. In MSM on cART, HCV had no significant effect on having a detectable HIV RNA viral load.
INTERPRETATION: Irrespective of the duration of HIV infection when HCV is acquired, CD4+ cell counts were temporarily lower following HCVsc, even when on cART. The clinical implications of our findings remain to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30325767      PMCID: PMC7116662          DOI: 10.1097/QAD.0000000000002040

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  28 in total

1.  Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.

Authors:  Martin Potter; Adefowope Odueyungbo; Hong Yang; Sahar Saeed; Marina B Klein
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

Review 2.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

3.  The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression Among Hepatitis C Virus-Infected Patients.

Authors:  Daniel S Fierer
Journal:  J Infect Dis       Date:  2016-08-02       Impact factor: 5.226

4.  Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

Authors: 
Journal:  HIV Med       Date:  2000-10       Impact factor: 3.180

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Authors:  Lionel Piroth; Linda Wittkop; Karine Lacombe; Eric Rosenthal; Camille Gilbert; Patrick Miailhes; Patrizia Carrieri; Julie Chas; Isabelle Poizot-Martin; Anne Gervais; Stéphanie Dominguez; Didier Neau; David Zucman; Eric Billaud; Philippe Morlat; Hugues Aumaitre; Caroline Lascoux-Combe; Anne Simon; Olivier Bouchaud; Elina Teicher; Firouzé Bani-Sadr; Laurent Alric; Daniel Vittecoq; François Boué; Claudine Duvivier; Marc-Antoine Valantin; Laure Esterle; François Dabis; Philippe Sogni; Dominique Salmon
Journal:  J Hepatol       Date:  2017-02-22       Impact factor: 25.083

Review 7.  HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Authors:  Eva A Operskalski; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

8.  Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.

Authors:  Daniela Katinka van Santen; Jannie Johanna van der Helm; Julia Del Amo; Laurence Meyer; Antonella D'Arminio Monforte; Matt Price; Charles Antoine Béguelin; Robert Zangerle; Mette Sannes; Kholoud Porter; Ronald Bertus Geskus; Maria Prins
Journal:  J Hepatol       Date:  2017-04-12       Impact factor: 25.083

Review 9.  Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy.

Authors:  Nicholas Petersdorf; Jennifer M Ross; Helen A Weiss; Ruanne V Barnabas; Judith N Wasserheit
Journal:  J Int AIDS Soc       Date:  2016-09-19       Impact factor: 5.396

10.  Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.

Authors:  Solomon Taye; Mekuria Lakew
Journal:  BMC Immunol       Date:  2013-05-17       Impact factor: 3.615

View more
  2 in total

Review 1.  A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.

Authors:  Samaa T Gobran; Petronela Ancuta; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

2.  Subtype-specific differences in transmission cluster dynamics of HIV-1 B and CRF01_AE in New South Wales, Australia.

Authors:  Francesca Di Giallonardo; Angie N Pinto; Phillip Keen; Ansari Shaik; Alex Carrera; Hanan Salem; Christine Selvey; Steven J Nigro; Neil Fraser; Karen Price; Joanne Holden; Frederick J Lee; Dominic E Dwyer; Benjamin R Bavinton; Jemma L Geoghegan; Andrew E Grulich; Anthony D Kelleher
Journal:  J Int AIDS Soc       Date:  2021-01       Impact factor: 6.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.